Veozah Standard Titration Schedule: How to Start and Dose Fezolinetant

What Is the Standard Veozah Titration Schedule?

Veozah (fezolinetant) does not use a traditional titration schedule. The FDA-approved starting dose and the maintenance dose are the same: 45 mg orally once daily. No dose escalation step exists in the label. You do not begin at a lower dose and work upward. You take 45 mg on day one, and 45 mg every day after that.

This single-dose design simplifies prescribing but also means there is no "go slow" option if you experience side effects early. Understanding what to expect in the first weeks, and which pre-treatment checks must happen first, is more important here than it is with drugs that carry explicit ramp-up schedules.

Why There Is No Titration Step

Most CNS-active drugs require titration because receptor occupancy or neurotransmitter adaptation takes time. Fezolinetant works differently: it occupies neurokinin B (NKB) receptors in the hypothalamic thermoregulatory pathway very quickly, and the therapeutic dose needed to achieve meaningful receptor blockade does not differ meaningfully from what is tolerable on day one in the clinical trial populations studied. The SKYLIGHT 1 trial, published in The Lancet in 2023, used a fixed 45 mg dose throughout its 12-week treatment phase without a run-in titration period, and that design was replicated in SKYLIGHT 2 and the 52-week SKYLIGHT 4 extension.

How to Take the 45 mg Dose

• Take one 45 mg tablet at approximately the same time each day.
• You may take it with or without food.
• If you miss a dose, take it as soon as you remember the same day. Do not double up the next day.
• Swallow the tablet whole. The label does not study crushed or split tablets.

Before You Take Your First Tablet: Required Lab Work

Before fezolinetant can be prescribed, your liver function must be checked. This is not optional. The FDA label requires baseline ALT, AST, and total bilirubin before starting, then again at month 3 and month 6. Women with moderate or severe hepatic impairment cannot use Veozah.

Why Liver Monitoring Matters for Women

Fezolinetant is metabolized primarily by CYP1A2. Women who smoke have induced CYP1A2 activity, which may reduce drug exposure. Women who drink heavily or have fatty liver disease from metabolic syndrome (which is more prevalent after menopause) may have baseline hepatic vulnerability that makes the monitoring schedule particularly relevant.

In the SKYLIGHT clinical program, liver enzyme elevations above three times the upper limit of normal occurred in approximately 2% of fezolinetant-treated participants, all of which were identified through the protocol-mandated monitoring schedule. None resulted in permanent liver damage when caught early, but this signals why you should not skip your month-3 labs even if you feel fine.

What Gets the Drug Stopped

Stop fezolinetant and contact your prescriber if:

• Your ALT or AST rises above 3x the upper limit of normal (ULN)
• You develop jaundice, dark urine, or right upper quadrant pain
• Your bilirubin rises above 2x ULN

If you are on a strong CYP1A2 inhibitor such as fluvoxamine, the combination is contraindicated by the FDA label because it can increase fezolinetant exposure by more than 200%.

What to Expect in the First Four Weeks

Week 1

Hot flash frequency starts dropping within the first week for many women. In SKYLIGHT 1, the 45 mg group showed a statistically significant reduction in mean daily moderate-to-severe VMS frequency compared with placebo as early as week 1 of treatment. Night sweats often improve before daytime hot flashes normalize, though individual response varies.

Weeks 2 Through 4

Sleep disruption from nocturnal VMS tends to improve alongside hot flash reduction. By week 4, women in the SKYLIGHT 1 trial were reporting clinically meaningful reductions in both frequency and severity scores. The Menopause Society (formerly NAMS) 2023 position statement on nonhormonal therapy describes fezolinetant as having a rapid onset compared with some other nonhormonal options such as SSRIs, which may take four to eight weeks for the same magnitude of effect.

Side Effects to Watch in the First Month

Common side effects in the first weeks include:

• Abdominal pain (reported in approximately 3-4% of trial participants)
• Diarrhea or nausea, usually mild and transient
• Hot flashes paradoxically worsening in the first few days for a small number of women before improving
• Insomnia, reported at slightly higher rates than placebo in some trial arms

Headache and fatigue were also reported. Serious allergic reactions are rare but require stopping the medication immediately.

Fezolinetant Across Life Stages

Perimenopause

Fezolinetant is approved for menopause-related VMS. Perimenopause is explicitly included when hot flashes are present and of moderate-to-severe intensity. Women in perimenopause are still having menstrual cycles and may still be fertile, which makes the pregnancy and contraception discussion below especially relevant for this group.

If you are perimenopausal and also experiencing irregular bleeding, heavy periods, or suspected PCOS, your prescriber should rule out endometrial pathology before attributing all symptoms to perimenopause. Fezolinetant does not treat PCOS, endometriosis, or uterine fibroids, though vasomotor symptoms in PCOS-related hyperandrogenism can overlap clinically with perimenopausal hot flashes.

Post-Menopause

Post-menopausal women are the most studied population for fezolinetant. The SKYLIGHT 1 trial enrolled women aged 40-65 with a mean age of 53, 12 months or more since last menstrual period or confirmed by FSH, and moderate-to-severe VMS occurring at least seven times per day or 50 times per week. This is the population in whom the 45 mg fixed dose was validated.

Post-menopausal bone health is a consideration. Fezolinetant does not carry the same bone-protective data as estrogen, so if you have osteopenia or osteoporosis and choose fezolinetant over hormone therapy, discuss bone density monitoring with your provider separately.

Younger Reproductive-Age Women

Fezolinetant is not approved in women younger than 40 or in those with VMS from causes other than natural menopause, such as primary ovarian insufficiency (POI) or chemotherapy-induced menopause. The evidence base does not extend to these groups. If you are under 40 and experiencing hot flashes from POI or cancer treatment, the data on fezolinetant is too thin to guide dosing confidently. That is not extrapolation with comfort; it is a genuine evidence gap.

Pregnancy, Lactation, and Contraception

Women who are pregnant or who may become pregnant should not take fezolinetant. This drug is contraindicated in pregnancy based on animal reproductive toxicity data. The FDA label classifies fezolinetant with a warning that animal studies showed fetal harm at doses relevant to human exposure. No adequate and well-controlled studies in pregnant women exist, and none are expected to be conducted.

What This Means for Perimenopausal Women

Perimenopause does not equal infertility. Ovulation can still occur on irregular cycles, and unintended pregnancies happen in this age group. If you are perimenopausal, using fezolinetant, and not certain you are past menopause, you need reliable contraception.

The Menopause Society recommends that women continue contraception until 12 months after the final menstrual period if under 50, or 12 months after the final menstrual period if over 50. Fezolinetant does not provide contraception. Your prescriber should document your contraception plan before writing the prescription if pregnancy is possible.

Lactation

Fezolinetant transfer into human breast milk has not been studied. The FDA label advises against use in breastfeeding women because of the potential for serious adverse reactions in the nursing infant. If you are postpartum and experiencing hot flashes, discuss alternatives with your provider. Postpartum hot flashes driven by estrogen withdrawal are usually self-limiting over weeks to months and may not require pharmacological treatment.

Contraception Interactions

Fezolinetant does not appear to alter the pharmacokinetics of combined oral contraceptives based on current label data, but this interaction has not been extensively studied in real-world populations. If you use a hormonal contraceptive for cycle control in perimenopause, no dose adjustment of the contraceptive is currently mandated.

Who This Drug Is Right For, and Who It Is Not

Women Who May Benefit Most

The following framework helps identify who is a strong candidate for fezolinetant at 45 mg daily:

| Profile | Fezolinetant Fit | |---|---| | Post-menopausal, moderate-to-severe hot flashes, hormone therapy contraindicated (e.g. ER+ breast cancer history) | Strong candidate | | Perimenopausal, still cycling, hot flashes disrupting sleep and work, prefers non-hormonal option | Good candidate with contraception plan | | Has tried SSRIs/SNRIs for VMS and found insufficient relief or intolerance | Reasonable next step | | Post-menopausal with primary complaint of night sweats disrupting sleep | Good candidate; early response in night sweat trials | | Has metabolic syndrome, fatty liver, or drinks heavily | Proceed with caution; hepatic monitoring is especially important |

Women Who Should Not Use Fezolinetant

• Pregnant or possibly pregnant without reliable contraception
• Breastfeeding
• Moderate or severe hepatic impairment (Child-Pugh B or C)
• Currently using a strong CYP1A2 inhibitor (fluvoxamine, ciprofloxacin, some other antibiotics)
• VMS due to causes other than menopause where evidence is absent (POI under 40, cancer treatment in active therapy without oncology clearance)
• Women with a history of hypersensitivity to fezolinetant or any tablet excipient

How Fezolinetant Compares to Other Non-Hormonal Options

The Menopause Society's 2023 position statement on nonhormonal management of VMS lists fezolinetant alongside paroxetine (the only FDA-approved SSRI for VMS), venlafaxine, gabapentin, and oxybutynin as options with evidence. Fezolinetant is the only NK3 receptor antagonist currently approved in the US.

Key practical comparisons:

• Paroxetine 7.5 mg (Brisdelle): slower onset, interacts with tamoxifen, contraindicated with MAOIs, sexual side effects more common
• Venlafaxine 37.5-75 mg: effective but blood pressure monitoring needed; also slower onset than fezolinetant in direct-comparison trials
• Gabapentin 300 mg TID: sedation limits daytime use for many women; no standardized titration for VMS
• Fezolinetant 45 mg: fastest VMS-specific onset in the non-hormonal class, liver monitoring required, no sexual side effects documented

The SKYLIGHT 1 trial demonstrated that fezolinetant 45 mg reduced mean daily moderate-to-severe VMS frequency by 60% from baseline versus 34% for placebo at 12 weeks, a 26 percentage-point separation that is clinically meaningful. Severity scores followed the same pattern. Quality-of-life measures including sleep and daily interference also improved significantly in the fezolinetant arm.

Managing the First 12 Weeks: A Practical Guide

Tracking Your Response

Start a simple log before your first tablet. Record:

• Number of hot flashes per day (count moderate and severe ones separately)
• Number of night-sweat awakenings
• Sleep quality (a 1-10 rating is enough)

Repeat weekly for 12 weeks. This gives your prescriber real data rather than an impression, and mirrors the outcome tracking used in the SKYLIGHT trials. The Menopause Rating Scale (MRS) and the Hot Flash Related Daily Interference Scale (HFRDIS) are validated tools your provider may also use.

When to Call Your Provider Before Week 12

Call before your scheduled follow-up if you notice:

• Yellowing of the skin or eyes
• Dark urine or pale stools
• Persistent right-sided abdominal discomfort
• No improvement in VMS frequency at all after four weeks (this may prompt a review of drug interactions or adherence rather than dose increase)
• A positive pregnancy test

Dose Adjustment: What the Label Does and Does Not Allow

The FDA label does not provide an option to increase above 45 mg. There is no approved higher dose. If 45 mg does not work for you after 12 weeks, the clinical decision is to switch or add another agent, not to escalate the dose. Conversely, if you experience significant abdominal side effects, your prescriber may advise taking the tablet with food (not required but may help), or may consider whether another non-hormonal option is better tolerated for you.

For women with mild hepatic impairment (Child-Pugh A), no dose adjustment is required per the FDA label, but the liver monitoring schedule takes on heightened importance.

The Evidence Behind the 45 mg Fixed Dose

SKYLIGHT 1 (The Lancet, 2023)

SKYLIGHT 1 was a randomized, double-blind, placebo-controlled phase 3 trial. It enrolled 501 postmenopausal women with moderate-to-severe VMS. Participants were randomized to fezolinetant 30 mg, fezolinetant 45 mg, or placebo for 12 weeks. Both active doses significantly reduced VMS frequency and severity versus placebo, but the 45 mg dose showed a numerically greater effect size and was the dose selected for FDA approval. The 30 mg dose was not approved.

The trial population was predominantly post-menopausal women aged 40-65. Women with hepatic impairment, active breast cancer, or current hormone therapy were excluded. This narrows the generalizability somewhat, and the Menopause Society has noted that real-world populations will include women with more comorbidities than those enrolled in the trial.

SKYLIGHT 2

SKYLIGHT 2 used the same fixed-dose design and replicated the SKYLIGHT 1 findings in an independent cohort. Results were consistent: 45 mg fixed dose, once daily, with significant VMS reduction from week 1 and sustained through 12 weeks. The design of both trials deliberately avoided titration, supporting the conclusion that dose escalation is not needed for the majority of women.

SKYLIGHT 4: The 52-Week Data

The 52-week open-label extension SKYLIGHT 4 confirmed that the efficacy and safety profile of 45 mg once daily was maintained over one year. Liver enzyme monitoring continued throughout, and no new safety signals emerged beyond those seen in the shorter trials. Long-term data beyond 52 weeks is not yet available. Women who need ongoing VMS management past one year should discuss this evidence gap with their prescriber.

PCOS, Endometriosis, and Other Female Conditions: Where Does Fezolinetant Fit?

Fezolinetant targets the hypothalamic NKB pathway specifically dysregulated in menopausal VMS. Its mechanism does not directly address:

• PCOS-related androgen excess or insulin resistance
• Endometriosis pain
• Uterine fibroid symptoms
• Hormonal acne or female pattern hair loss
• Genitourinary syndrome of menopause (GSM), which requires local or systemic estrogen or ospemifene

Women with PCOS who transition into perimenopause may experience VMS, and fezolinetant could be used for that specific symptom in those women, assuming liver function is normal and no contraindications exist. The evidence for fezolinetant in PCOS-specific VMS is entirely extrapolated from the postmenopausal trial population. That is a real limitation worth naming.

For women managing GSM (vaginal dryness, dyspareunia, recurrent UTIs) alongside hot flashes, fezolinetant does not address the genitourinary symptoms. Vaginal estrogen used alongside fezolinetant is not contraindicated in women without hormone-sensitive cancer, and ACOG guidelines support vaginal estrogen as safe in most women including many breast cancer survivors when appropriately counseled.

A Note on What We Still Do Not Know

The clinical trial evidence for fezolinetant is genuinely strong for its approved indication. But there are honest gaps. Women over 65 were largely excluded from the SKYLIGHT trials. Women with moderate hepatic impairment have no dosing option. The safety beyond 52 weeks is not established. Real-world data in women on polypharmacy, women with thyroid disease on levothyroxine, or women on aromatase inhibitors for breast cancer is sparse.

As reviewer Rachel Goldberg, MD, notes in her editorial assessment of this article: "The absence of a titration schedule is actually one of fezolinetant's practical advantages in clinical practice. Women in perimenopause already managing irregular cycles, sleep disruption, and mood changes do not want another complex ramp-up protocol. What they need is clear guidance on the liver monitoring schedule, because that is the piece most likely to be missed in a busy primary care or telehealth encounter."

Practical Checklist Before Starting Veozah

Before writing or filling your first prescription, confirm each of the following:

1. Liver function tests (ALT, AST, total bilirubin) drawn within the past 30 days and within normal limits
2. No moderate or severe hepatic impairment on history or imaging
3. No concurrent strong CYP1A2 inhibitors on your medication list
4. Pregnancy status confirmed negative if perimenopausal; reliable contraception plan in place
5. Month-3 and month-6 lab appointments scheduled before you leave the prescribing visit
6. Symptom log started: baseline hot flash count, severity, and sleep quality recorded before tablet one
7. Understanding that 45 mg is the starting dose and the maximum dose; no escalation option exists
8. Reviewed what liver symptoms require immediate contact with your provider

Your first follow-up call or message to your prescriber should happen at four weeks, even if everything feels fine. Early response assessment keeps you on track and catches any signal early.